Aegle Therapeutics
Developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells to treat severe dermatological conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 | round | |
$3.0m | Convertible | ||
| Total Funding | 000k | ||
Related Content
Aegle Therapeutics is a pioneering biotech company specializing in the development of exosome-based therapies. These therapies utilize a proprietary isolation technology to safely and efficiently isolate clinical-grade exosomes, which harness the regenerative healing power of stem cells without the associated risks of cell proliferation or engraftment. The company's core product, EV therapy, is cell-free and offers a safer, lower-cost alternative for regenerative medicine. Aegle Therapeutics primarily serves patients with complex tissue disorders, including those suffering from dystrophic epidermolysis bullosa (DEB), a rare genetic skin condition. Operating within the regenerative medicine market, Aegle's business model focuses on research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, grants, and future sales of approved therapies.
Keywords: exosome-based therapy, regenerative medicine, stem cell healing, clinical-grade exosomes, proprietary isolation technology, cell-free therapy, dystrophic epidermolysis bullosa, complex tissue disorders, biotech, innovative treatments.